ERBB2 and urinary bladder cancer: Research performed in bladder cancer cell lines revealed a rapid induction of HER2 and HER3 in cells treated with the FGFR inhibitor, BGJ398, thus suggesting that a switch from FGFR- to HER2/3-dependency can compensate FGFR inhibition (17).